Continuous response with nemolizumab up to 56 weeks during a long-term extension study in patients with moderate-to-severe atopic dermatitis and partial or delayed skin response at Week 16 e Post-hoc analyses from the pooled ARCADIA 1&2 trials and long-te

Verbundene Inhalte

• Publikationen

• Continuous response with nemolizumab up to 56 weeks during a long-term extension study in patients with moderate-to-severe atopic dermatitis and partial or delayed skin response at Week 16 e Post-hoc analyses from the pooled ARCADIA 1&2 trials and long-te

  Publikation: Beitrag in Fachzeitschrift › Konferenzabstract